Longeveron Inc. Engages in Vital Investor Conversations
MIAMI, Oct. 06, 2025 – Longeveron Inc. (NASDAQ: LGVN), a pioneering biotechnology company devoted to developing cutting-edge cellular therapies, is thrilled to announce its participation in the 4th Annual ROTH Healthcare Opportunities Conference. This prestigious event will provide an excellent platform for Longeveron to connect with potential investors and stakeholders.
Details of the Event
Scheduled to occur on October 9, 2025, in New York, this conference aims to foster intimate discussions between company leadership and a select group of investors. Longeveron's management team is eager to conduct one-on-one meetings to delve deeper into the company's innovative projects and the future of regenerative medicine.
About Longeveron Inc.
Longeveron Inc. is at the forefront of regenerative medicine, dedicated to addressing critical unmet medical needs with its innovative therapies. The company's flagship investigational product, laromestrocel—also known as Lomecel-B™—is derived from mesenchymal stem cells (MSCs) sourced from the bone marrow of young, healthy adult donors. This unique therapy harbors multiple mechanisms of action, offering therapeutic potential across various disease areas, including pro-vascular, anti-inflammatory, and tissue healing properties.
Pipeline of Innovative Therapies
Currently, Longeveron is focusing on four promising indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, Pediatric Dilated Cardiomyopathy (DCM), and aging-related frailty. Each of these conditions represents significant challenges in medical treatment, highlighting the pressing need for solutions that enhance patient outcomes.
Regulatory Milestones Achieved
Longeveron’s commitment to innovation has been recognized by the U.S. Food and Drug Administration (FDA), which has granted essential designations to its development programs. The HLHS initiative has received Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation, while the Alzheimer’s program was honored with both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. These acknowledgments underscore the company’s position in the competitive biotechnology landscape.
Future Directions and Investor Relations
As Longeveron Inc. continues to advance its pipeline and refine its therapeutic approaches, it stands committed to transparency and collaboration with investors. The upcoming ROTH Healthcare Opportunities Conference presents a pivotal opportunity to share insights about its strategic path and growth within the biotechnology sector. Investors are encouraged to engage in meaningful dialogues with the leadership team to explore how they can contribute to Longeveron's vision and success.
Stay Connected with Longeveron Inc.
For more insights and updates regarding Longeveron's projects and research initiatives, interested parties can visit the company’s official website or connect on social media platforms such as LinkedIn, X, and Instagram.
Investor and Media Contact
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
Frequently Asked Questions
What is Longeveron Inc. known for?
Longeveron Inc. is known for its innovative work in cellular therapies aimed at treating rare diseases and conditions related to aging.
When and where is the ROTH Healthcare Opportunities Conference?
The conference will take place on October 9, 2025, in New York, serving as an opportunity for Longeveron to engage with investors.
What are the main products being developed by Longeveron?
Longeveron is primarily developing laromestrocel (Lomecel-B™), a stem cell therapy focusing on diseases like HLHS, Alzheimer’s, and DCM.
What regulatory designations has Longeveron received?
Longeveron has achieved several FDA designations, including Orphan Drug, Fast Track, and Rare Pediatric Disease for its HLHS program.
How can investors learn more about Longeveron?
Investors can visit Longeveron's website or follow the company on social media platforms to stay updated on news and progress.
